NeuroSense Therapeutics Ltd. (NRSN) - סך הכנסות החברה

NeuroSense Therapeutics (NRSN) develops therapies for ALS and Alzheimer's disease while strictly adhering to biohazardous waste disposal standards. The company's commercial sales volume visualizes actual cash flow without speculation, with the indicator reaching 0.00. High business scalability is driven by patents that enable the global distribution of innovative drugs with minimal production costs.

NeuroSense Therapeutics (NRSN) maintains a strong position in the neurodegenerative pathology sector thanks to a diversified patent portfolio. By analyzing the company's gross sales revenue, an investor can see the actual daily cash inflow from clients. This metric captures real liquidity and allows for the prompt detection of cash gaps or deviations from the financial plan. Stable growth in this indicator confirms the commercial viability of current clinical trial programs.